[HTML][HTML] Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics

H Padinharayil, J Varghese, MC John, GK Rajanikant… - Genes & …, 2023 - Elsevier
Continuous revision of the histologic and stage-wise classification of lung cancer by the
World Health Organization (WHO) provides the foundation for therapeutic advances by …

[HTML][HTML] Exosome nanovesicles as potential biomarkers and immune checkpoint signaling modulators in lung cancer microenvironment: recent advances and …

NA Khan, M Asim, KH Biswas, AN Alansari… - Journal of Experimental …, 2023 - Springer
Lung cancer remains the leading cause of cancer-related deaths globally, and the survival
rate remains low despite advances in diagnosis and treatment. The progression of lung …

[HTML][HTML] Circulating tumour cells and PD-L1-positive small extracellular vesicles: the liquid biopsy combination for prognostic information in patients with metastatic …

Z Eslami-S, LE Cortés-Hernández, L Sinoquet… - British Journal of …, 2024 - nature.com
Abstract Background Circulating tumour cells (CTCs), circulating tumour DNA (ctDNA), and
extracellular vesicles (EVs) are minimally invasive liquid biopsy biomarkers. This study …

[HTML][HTML] Network approach in liquidomics landscape

D Santini, A Botticelli, A Galvano, M Iuliani… - Journal of Experimental …, 2023 - Springer
Tissue-based biopsy is the present main tool to explore the molecular landscape of cancer,
but it also has many limits to be frequently executed, being too invasive with the risk of side …

The evolving role of liquid biopsy in lung cancer

U Malapelle, P Pisapia, F Pepe, G Russo, M Buono… - Lung Cancer, 2022 - Elsevier
Liquid biopsy has revolutionized the management of cancer patients. In particular, liquid
biopsy-based testing has proven to be highly beneficial for identifying actionable cancer …

[HTML][HTML] Extracellular vesicle-based liquid biopsy biomarkers and their application in precision immuno-oncology

K Asleh, V Dery, C Taylor, M Davey… - Biomarker …, 2023 - Springer
While the field of precision oncology is rapidly expanding and more targeted options are
revolutionizing cancer treatment paradigms, therapeutic resistance particularly to …

[HTML][HTML] Prognostic role of soluble and extracellular vesicle-associated PD-L1, B7-H3 and B7-H4 in non-small cell lung cancer patients treated with immune …

C Genova, R Tasso, A Rosa, G Rossi, D Reverberi… - Cells, 2023 - mdpi.com
The treatment of non-small cell lung cancer (NSCLC) has changed dramatically with the
advent of immune checkpoint inhibitors (ICIs). Despite encouraging results, their efficacy …

Baseline extracellular vesicle TGF‐β is a predictive biomarker for response to immune checkpoint inhibitors and survival in non–small cell lung cancer

D de Miguel‐Perez, A Russo, M Gunasekaran… - Cancer, 2023 - Wiley Online Library
Abstract Background Immune‐checkpoint inhibitors (ICIs) are an effective therapeutic
strategy, improving the survival of patients with lung cancer compared with conventional …

Lung cancer associated with combustion particles and fine particulate matter (PM2. 5)-The roles of polycyclic aromatic hydrocarbons (PAHs) and the aryl hydrocarbon …

JA Holme, J Vondráček, M Machala… - Biochemical …, 2023 - Elsevier
Air pollution is the leading cause of lung cancer after tobacco smoking, contributing to 20%
of all lung cancer deaths. Increased risk associated with living near trafficked roads …

Liquid biopsy response evaluation criteria in solid tumors (LB-RECIST)

MA Gouda, F Janku, A Wahida, L Buschhorn… - Annals of …, 2023 - Elsevier
Current evaluation of treatment response in solid tumors depends on dynamic changes in
tumor diameters as measured by imaging. However, these changes can only be detected …